Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)

Market Cap	75.77B
Revenue (ttm)	85.92B
Net Income (ttm)	12.65B
Shares Out	11.38M
EPS (ttm)	1,094.66
PE Ratio	6.08
Forward PE	n/a
Dividend	190.00 (2.87%)
Ex-Dividend Date	Dec 27, 2024

Volume	24,164
Average Volume	131,264
Open	6,640.00
Previous Close	6,710.00
Day's Range	6,590.00 - 6,680.00
52-Week Range	5,920.00 - 8,430.00
Beta	1.46
RSI	50.97
Earnings Date	Aug 12, 2025

About Sinil Pharmaceutical

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, including skin care products, etc.; health functional products comprising vitamin supplements; and quasi-drugs for yellow dust, bacteria blocking, etc. In ...

• Industry: Pharmaceutical Preparations
• Founded: 1971
• Employees: 287
• Stock Exchange: KOSDAQ
• Ticker Symbol: 012790

Financial Performance

In 2024, Sinil Pharmaceutical's revenue was 89.44 billion, an increase of 0.34% compared to the previous year's 89.14 billion. Earnings were 14.30 billion, an increase of 4.83%.